Gumlink and Fertin Pharma have initiated legal proceedings against British-based firm Revolymer for allegedly infringing Gumlink’s patent on a degradable gum base by selling nicotine gum in Canada. Revolymer plans to defend its position.
December 14 brings the long awaited and widely disputed EU crack down on health claims. That means 222 general function claims are good to go, another 1500 or so prohibited. But what happens to B2B communications?